Regeneron’s gene therapy triumphs twice, restoring hearing in children
The two children with rare genetic otoferlin hearing loss enrolled in the Phase I/II trial for Regeneron’s gene therapy observed improvements in hearing.
09 May 2024
09 May 2024
The two children with rare genetic otoferlin hearing loss enrolled in the Phase I/II trial for Regeneron’s gene therapy observed improvements in hearing.
The transformative potential of decentralised clinical trials (DCTs) has been heralded in recent years.
Regenex Bio will sit down with the FDA in Q3 2024 to finalise the Phase III trial design.
The preliminary data indicates potential benefits for non-Hodgkin's lymphoma patients.
TEV-‘749 has met primary endpoint in Phase III trial, showing significant symptom reduction in schizophrenia patients.
The Phase I placebo-controlled trial aims to assess the safety and tolerability of NS-136 in healthy participants.
The collaboration will focus on evaluating Phanes' antibody PT217 in combination with Roche's atezolizumab.
The report published by the Medicines Discovery Catapult warns that a mix of economic uncertainty and lack of facility access is pushing investors away from Britain’s healthcare SMEs.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.